Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeBiotech

      Biotech

      Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
      Biotech

      Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates

      November 1, 2022
      REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE(TM) Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
      Biotech

      REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE(TM) Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

      August 31, 2022
      Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
      Biotech

      Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

      August 31, 2022
      Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
      Biotech

      Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT

      August 31, 2022
      FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
      Biotech

      FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

      August 31, 2022
      NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING
      Biotech

      NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

      August 31, 2022
      argenx to Present at Wells Fargo Healthcare Conference
      Biotech

      argenx to Present at Wells Fargo Healthcare Conference

      August 31, 2022
      Ionis to present at upcoming investor conferences
      Biotech

      Ionis to present at upcoming investor conferences

      August 31, 2022
      BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE
      Biotech

      BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE

      August 31, 2022
      Roivant to Participate in September Investor Events
      Biotech

      Roivant to Participate in September Investor Events

      August 31, 2022
      « 1 … 131 132 133 134 135 … 150 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026